KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) Equity Average (2016 - 2025)

Resmed (RMD) has disclosed Equity Average for 16 consecutive years, with $6.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 19.09% year-over-year to $6.2 billion, compared with a TTM value of $6.2 billion through Dec 2025, up 19.09%, and an annual FY2025 reading of $5.4 billion, up 20.44% over the prior year.
  • Equity Average was $6.2 billion for Q4 2025 at Resmed, up from $6.0 billion in the prior quarter.
  • Across five years, Equity Average topped out at $6.2 billion in Q4 2025 and bottomed at $2.8 billion in Q1 2021.
  • Average Equity Average over 5 years is $4.2 billion, with a median of $4.1 billion recorded in 2023.
  • Peak annual rise in Equity Average hit 23.47% in 2021, while the deepest fall reached 11.33% in 2021.
  • Year by year, Equity Average stood at $3.1 billion in 2021, then increased by 16.19% to $3.6 billion in 2022, then grew by 21.77% to $4.4 billion in 2023, then grew by 19.65% to $5.2 billion in 2024, then increased by 19.09% to $6.2 billion in 2025.
  • Business Quant data shows Equity Average for RMD at $6.2 billion in Q4 2025, $6.0 billion in Q3 2025, and $5.8 billion in Q2 2025.